Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Director | May 28, 2021 | June 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date May 28, 2021 · Filed June 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.92 · Expires 2031-05-28 | Direct | 3,750 |
Reported balance
After 2021-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-28 · Grant · Acquired 3,750 · Balance 3,750 F1: The shares subject to the option shall vest 25% every quarter after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest 25% every quarter after the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2021 Filed Jun 2, 2021 00:00 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-21-075258 · tm2118079-10_4seq1.xml · derivative · entry 1 Widlitz Michael · CIK 0001826907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest 25% every quarter after the grant date. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 01:20 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001104659-20-122037 · a4.xml · derivative · entry 1 Widlitz Michael · CIK 0001826907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-11-03 F1 · security: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter. F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:17 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionSeries A Convertible Preferred Stock · Derivative | 51,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054319 · doc4.xml · derivative · entry 2 Widlitz Michael · CIK 0001826907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:17 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionCommon Stock | 51,315 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054319 · doc4.xml · nonDerivative · entry 1 Widlitz Michael · CIK 0001826907 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.